The decision to undergo radical prostatectomy, or any treatment for prostate cancer, is of course not an easy one. Dr. Andrew Wagner, Director of Minimally-Invasive Urologic Surgery at Beth Israel Deaconess Medical Center, provides some guidance if you are considering this procedure.
Sexual health is important at any age. Intimacy is a key part of any romantic relationship. But for many men age 65 and over, sex is becoming just a memory.
The recent recommendation by the U.S. Preventive Services Task Force (USPSTF), a government panel, against routine PSA-based screening for prostate cancer is sparking a great deal of debate in medical circles–and likely causing confusion for patients.
Physicians are now better able to predict a man’s recovery of sexual function after prostate cancer treatment, making a conversation between doctor and patient an important part of pre-treatment planning, a Beth Israel Deaconess Medical Center-led research team suggests.
More and more, men diagnosed with low grade prostate cancer are choosing to defer treatment, preferring to monitor the status of their cancer by having regular blood tests and tissue biopsies that are designed to let them know if they need to be treated or if they can continue to hold off.
For men diagnosed with advanced prostate cancer, available treatments run the gamut from radiation, hormonal and chemotherapy to a costly new-to-the market, first-generation prostate cancer vaccine.
An estimated 240,000 American men will be diagnosed with prostate cancer this year. Not all men will need or select to have a prostatectomy (surgery to remove the prostate gland), but for those that do, having a clear understanding of possible post-surgery outcomes, such as sexual and urinary function, is critical.